← All Molecular Partners AG filings

Molecular Partners AG 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
MOLN
Molecular Partners AG
20-F: Molecular Partners 2025: Pipeline Advances, Losses Persist
Molecular Partners AG reported continued net losses in 2025, alongside significant progress in its oncology pipeline, including the initiation of new clinical trials and expansion of strategic collaborations for its DARPin therapeutics.
NASDAQ
MOLN
Molecular Partners AG
20-F: Molecular Partners AG Files 20-F Report for Fiscal Year Ended December 31, 2024
Molecular Partners AG releases its annual report on Form 20-F, detailing its financial results and operational activities for the fiscal year ending December 31, 2024.
NASDAQ
MOLN
Molecular Partners AG
20-F: Molecular Partners and Orano Med Expand Collaboration to Develop Novel Cancer Therapies
Molecular Partners and Orano Med are expanding their collaboration to develop novel radioligand therapies for cancer treatment, focusing on DLL3 and other targets.